These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1839022)

  • 1. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
    Huhtaniemi I; Parvinen M; Venho P; Rannikko S
    Int J Androl; 1991 Oct; 14(5):374-86. PubMed ID: 1839022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
    Faure N; Lemay A; Laroche B; Robert G; Plante R; Jean C; Thabet M; Roy R; Fazekas AT
    Prostate; 1983; 4(6):601-24. PubMed ID: 6415632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J; Williams G; Sandow J; Hewitt G; Abel P; Farah N; Fleming J; Cox J; O'Donoghue EP; Sikora K
    Am J Clin Oncol; 1988; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
    Huhtaniemi I; Nikula H; Rannikko S
    J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer.
    Rost A; Schmidt-Gollwitzer M; Hantelmann W; Brosig W
    Prostate; 1981; 2(3):315-22. PubMed ID: 6458025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of pituitary-testis function in rats treated neonatally with a gonadotrophin-releasing hormone agonist and antagonist: acute and long-term effects.
    Kolho KL; Huhtaniemi I
    J Endocrinol; 1989 Oct; 123(1):83-91. PubMed ID: 2509621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
    Huhtaniemi I; Nikula H; Rannikko S; Clayton R
    J Steroid Biochem; 1986 Jan; 24(1):169-76. PubMed ID: 3009972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
    Varenhorst E; Wallentin L; Carlström K
    Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
    Huhtaniemi I; Nikula H; Rannikko S
    J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
    Di Silverio F; Serio M; D'Eramo G; Sciarra F
    Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer.
    Properzi G; Francavilla S; Vicentini C; Cordeschi G; Galassi P; Paradiso Galatioto G; Miano L
    Eur Urol; 1989; 16(6):426-32. PubMed ID: 2531668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men.
    Knuth UA; Hano R; Nieschlag E
    J Clin Endocrinol Metab; 1984 Nov; 59(5):963-9. PubMed ID: 6237116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary-testicular function in immature rats after treatment with GnRH antagonist, GnRH antiserum and bromocriptine.
    Huhtaniemi IT; Stewart JM; Channabasavaiah K; Fraser HM; Clayton RN
    Mol Cell Endocrinol; 1984 Feb; 34(2):137-43. PubMed ID: 6325270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis.
    Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
    J Androl; 1987; 8(6):363-73. PubMed ID: 3123446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
    Boccon-Gibod L; Laudat MH; Dugue MA; Steg A
    Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.